What is the recommended dosage of Zovirax (acyclovir) for treating shingles?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 23, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Acyclovir Dosing for Shingles (Herpes Zoster)

For acute treatment of shingles, the recommended dose of Zovirax (acyclovir) is 800 mg orally five times daily for 7 to 10 days, initiated within 72 hours of rash onset for maximum benefit. 1

Standard Oral Dosing Regimen

  • The FDA-approved dosing for herpes zoster is acyclovir 800 mg orally every 4 hours, five times daily for 7 to 10 days 1
  • This high-dose regimen (800 mg five times daily) is significantly superior to lower doses (400 mg five times daily), demonstrating accelerated viral clearance, faster time to 50% scabbing and healing, reduced new lesion formation, and decreased severity of acute pain 2, 3
  • Treatment must be started within 72 hours of rash appearance for optimal efficacy 4

Intravenous Therapy for Severe Disease

  • For severe disease, complications, disseminated zoster, or hospitalized patients, the CDC recommends acyclovir 5-10 mg/kg IV every 8 hours for 5-7 days or until clinical improvement 5
  • IV therapy is particularly important for immunocompromised patients to halt viral dissemination and prevent visceral complications 3
  • At these higher IV doses, adequate hydration and urine flow must be maintained, mental status monitored, and dosing adjusted downward for impaired renal function 3

Renal Dose Adjustments

  • For creatinine clearance 10-25 mL/min: reduce to 800 mg every 8 hours 1
  • For creatinine clearance 0-10 mL/min: reduce to 800 mg every 12 hours 1
  • For hemodialysis patients, administer an additional dose after each dialysis session due to 60% reduction in plasma concentrations during a 6-hour dialysis period 1

Special Populations: Immunocompromised Patients

  • Immunocompromised patients (including HIV-infected individuals) require more aggressive therapy with higher doses or IV administration 5, 6
  • For AIDS patients with herpes zoster, one approach is 800 mg oral acyclovir five or six times daily for 5-10 days depending on response, with potential benefit from concomitant topical acyclovir 6
  • These patients may need suppressive therapy with acyclovir 400 mg orally 3-5 times daily to prevent recurrences 5

Critical Timing Considerations

  • Therapy should be initiated within 72 hours of rash onset - treatment started after this window has significantly reduced effectiveness 4
  • Early initiation during the prodrome or at first sign of lesions provides maximum benefit for reducing acute pain duration and severity 2

Important Caveats to Avoid Common Pitfalls

  • Never use topical acyclovir for herpes zoster - it is substantially less effective than oral therapy and provides no meaningful clinical benefit 5
  • Acyclovir does not eradicate latent varicella-zoster virus and does not prevent future recurrences after discontinuation 5
  • While the 800 mg five times daily regimen reduces acute pain and may decrease early postherpetic neuralgia (particularly in the first 3 months), it has not been definitively proven to prevent long-term postherpetic neuralgia 2, 7

Alternative Antiviral Options

  • Valacyclovir 1000 mg three times daily for 7 days offers comparable efficacy with simpler dosing (accelerates pain resolution with median duration 38 days versus 51 days for acyclovir) and maintains the favorable safety profile 7
  • Famciclovir 500 mg twice daily for 7 days demonstrates comparable efficacy to acyclovir 800 mg five times daily with more convenient dosing 4

References

Research

Therapy of herpes zoster with oral acyclovir.

The American journal of medicine, 1988

Research

Antiviral treatment in chickenpox and herpes zoster.

Journal of the American Academy of Dermatology, 1988

Guideline

Acyclovir Dosing for Herpes Zoster

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.